Inclisiran demonstrated sustained and effective LDL cholesterol reduction in patients with or at risk of atherosclerotic cardiovascular disease, regardless of baseline eGFR as low as 15 mL/min/1.73m2, without new safety findings.
Landmesser et al. (Wed,) studied this question.